Xencor (XNCR) Income from Non-Controlling Interests (2023 - 2025)
Xencor (XNCR) reported Income from Non-Controlling Interests of -$214000.0 for Q1 2025, up 68.34% year-over-year from -$127121.3 in Q1 2024, and up 66.92% quarter-over-quarter from -$647000.0 in Q4 2024.
Xencor (XNCR) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Xencor (XNCR) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$214000.0 in Q1 2025.
- Income from Non-Controlling Interests for Q1 2025 came in at -$214000.0, up 68.34% year-over-year; the trailing twelve-month figure through Dec 2025 was -$214000.0 (up 94.54% YoY), and the FY2025 annual result was -$214000.0, up 94.54% from the prior year.
- Income from Non-Controlling Interests advanced to -$214000.0 in Q1 2025 per XNCR's latest filing, from -$647000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$163000.0 in Q4 2023 and troughed at -$1.4 million in Q2 2024.
- A 3-year average of -$716500.0 and a median of -$661500.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests slumped 296.93% in 2024, then jumped 68.34% in 2025.
- A 3-year view of Income from Non-Controlling Interests shows it stood at -$163000.0 in 2023, then tumbled by 296.93% to -$647000.0 in 2024, then soared by 66.92% to -$214000.0 in 2025.
- Business Quant data shows XNCR's Income from Non-Controlling Interests at -$214000.0 in Q1 2025, -$647000.0 in Q4 2024, and -$1.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -214,000.00 |
| Dec 31, 2024 | -647,000.00 |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.45 Mn |
| Mar 31, 2024 | -676,000.00 |
| Dec 31, 2023 | -163,000.00 |